Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Baulard

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Journal of Medicinal Chemistry|June 29, 2012
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesisMarion Flipo, Nicolas Willand, Nathalie Lecat-Guillet, et al.
Nature Medicine|May 5, 2009
Synthetic EthR inhibitors boost antituberculous activity of ethionamideNicolas Willand, Bertrand Dirié, Xavier Carette, et al.
Journal of Medicinal Chemistry|May 14, 2014
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approachesBaptiste Villemagne, Marion Flipo, Nicolas Blondiaux, et al.
Journal of Medicinal Chemistry|March 23, 2011
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitorsMarion Flipo, Matthieu Desroses, Nathalie Lecat-Guillet, et al.
Nucleic Acids Research|December 14, 2011
Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligandsXavier Carette, Nicolas Blondiaux, Eve Willery, et al.
European Journal of Medicinal Chemistry|June 7, 2020
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screeningLéo Faïon, Kamel Djaout, Rosangela Frita, et al.
Journal of Medicinal Chemistry|November 22, 2011
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitorsMarion Flipo, Matthieu Desroses, Nathalie Lecat-Guillet, et al.
Science (New York, N.Y.)|March 18, 2017
Reversion of antibiotic resistance in <i>Mycobacterium tuberculosis</i> by spiroisoxazoline SMARt-420Nicolas Blondiaux, Martin Moune, Matthieu Desroses, et al.
ACS Nano|March 2, 2019
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against TuberculosisArnaud Machelart, Giuseppina Salzano, Xue Li, et al.
Chemistry & Biology|June 23, 2015
Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrGGiorgia Mori, Laurent R Chiarelli, Marta Esposito, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Journal of Medicinal Chemistry|June 29, 2012
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesisMarion Flipo, Nicolas Willand, Nathalie Lecat-Guillet, et al.
Nature Medicine|May 5, 2009
Synthetic EthR inhibitors boost antituberculous activity of ethionamideNicolas Willand, Bertrand Dirié, Xavier Carette, et al.
Journal of Medicinal Chemistry|May 14, 2014
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approachesBaptiste Villemagne, Marion Flipo, Nicolas Blondiaux, et al.
Journal of Medicinal Chemistry|March 23, 2011
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitorsMarion Flipo, Matthieu Desroses, Nathalie Lecat-Guillet, et al.
Nucleic Acids Research|December 14, 2011
Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligandsXavier Carette, Nicolas Blondiaux, Eve Willery, et al.
European Journal of Medicinal Chemistry|June 7, 2020
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screeningLéo Faïon, Kamel Djaout, Rosangela Frita, et al.
Journal of Medicinal Chemistry|November 22, 2011
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitorsMarion Flipo, Matthieu Desroses, Nathalie Lecat-Guillet, et al.
Science (New York, N.Y.)|March 18, 2017
Reversion of antibiotic resistance in <i>Mycobacterium tuberculosis</i> by spiroisoxazoline SMARt-420Nicolas Blondiaux, Martin Moune, Matthieu Desroses, et al.
ACS Nano|March 2, 2019
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against TuberculosisArnaud Machelart, Giuseppina Salzano, Xue Li, et al.
Chemistry & Biology|June 23, 2015
Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrGGiorgia Mori, Laurent R Chiarelli, Marta Esposito, et al.
Pageof 6